Home › Trial NCT06987734
Neoadjuvant Sugemalimab + Chemotherapy Followed by Adjuvant Sugemalimab for Patients With Resectable Stage II-IIIA Non-small-cell Lung Cancer Patients
- Trial IDNCT06987734
- StatusRecruiting
- PhasePhase 2
- Study typeInterventional
- SponsorShanghai Pulmonary Hospital, Shanghai, China
- Enrollment25
- Start date2025-06-19
- ConditionsLung Cancer (NSCLC)
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.